Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized 
anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai 
Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and 
several types of arthritis. The product is approved in the European Union for 
treatment of moderate-to-severe rheumatoid arthritis, and is currently 
undergoing review by the US Food and Drug Administration for this condition. 
Tocilizumab has also been studied for potential use in the treatment of other 
IL-6 related disorders including Crohn disease.